T-Cells are crucial immune cells capable of recognising cancers over healthy cells. Utilising the immune system to recognise and destroy tumour cells has been the primary goal of anti-cancer immunotherapy.
Recently, there has been an increased interest in optimising this methodology to make it feasible for clinical treatment. One of the treatment modalities within cancer immunotherapy has been adoptive T cell therapy. This treatment involves infusing tumour-specific cytotoxic T cells in cancer patients to locate and destroy tumour cells.